ThinkSono has successfully closed an oversubscribed funding round, raising £2.1 million. The round, led by id4 ventures and supported by several key investors, brings the company’s total funding to £5 million. This capital injection will fuel ThinkSono’s mission to transform patient care globally with its AI ultrasound guidance solutions.
Concurrently, ThinkSono has earned the Class IIb CE mark for its flagship ThinkSono Guidance system, which empowers healthcare staff to detect blood clots (DVT) efficiently, a major cause of preventable hospital deaths. The company’s expansion into the European market is complemented by strategic partnerships with NYU Langone Health and Temple Health in the U.S., marking a critical step towards FDA approval.
Fouad Al Noor, CEO of ThinkSono, expressed excitement over the funding and regulatory achievements, emphasizing their commitment to improving patient outcomes with innovative technology. ThinkSono’s CMO, Michael Blaivas, highlighted the technology’s potential to revolutionize DVT diagnosis and treatment, impacting a wide range of healthcare settings.
FERMAT secures $17 million funding in a round led by Bain Capital Ventures